TCL科技(000100.SZ)逼近漲停股價創歷史新高 26億可轉債獲3倍超額認購
格隆匯12月2日丨TCL科技(000100.SZ)盤中一度漲9.89%報8元,逼近漲停,股價創歷史新高,市值1080億元。公司最新公告,26億元可轉換債券成功發行,共有54家機構及個人進行認購,其中不乏中國人壽、工銀瑞信、嘉實基金、高瓴資本、摩根大通等主流公募基金、保險、知名投資公司以及國際投行的參與,認購總金額近百億元,超過26億元配套資金的3倍。據機構的報價結果,此次TCL科技26億元配套資金可轉債初始轉股價格為8.00元/股,不僅遠高於前20個交易日的股票均價,而且高於當天二級市場收盤價,轉股價格較二級市場溢價率達11%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.